Literature DB >> 18351689

Multiple sclerosis-related proteins identified in cerebrospinal fluid by advanced mass spectrometry.

Marcel P Stoop1, Lennard J Dekker, Mark K Titulaer, Peter C Burgers, Peter A E Sillevis Smitt, Theo M Luider, Rogier Q Hintzen.   

Abstract

A total of 164 cerebrospinal fluid (CSF) samples taken from neurological patients were classed into four groups according to the clinical diagnosis: multiple sclerosis (MScl, n = 44), clinically isolated syndrome of demyelination (CIS, n = 40), other inflammatory neurological disease (OIND, n = 26) and other neurological disease (OND, n = 54). After tryptic digestion, the samples were measured by MALDI-TOF MS. Spectra were analyzed using the R-project software package, in which a peak detection algorithm was developed. Subsequently, the peak lists were compared based on ranked data (non-parametric). Significant differences were observed in the comparisons of MScl vs. OND and CIS vs. OND. The comparisons of MScl vs. OIND, and CIS vs. OIND showed fewer significant differences. No significant differences were found in comparisons MScl vs. CIS and OIND vs. OND. MScl and CIS had strikingly similar profiles, probably a reflection of common pathological mechanisms. Three differentially expressed proteins in the comparison of MScl vs. OND were identified: chromogranin A, a potential marker for neurodegeneration; and two important factors in complement-mediated inflammatory reaction, clusterin and complement C3. CSF chromogranin A levels were confirmed to be significantly elevated in the MScl group using an ELISA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18351689     DOI: 10.1002/pmic.200700446

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  18 in total

Review 1.  Proteomic studies on the development of the central nervous system and beyond.

Authors:  Chenggang Zhang
Journal:  Neurochem Res       Date:  2010-06-25       Impact factor: 3.996

2.  Biomarkers of HIV-1-associated neurocognitive disorders: challenges of proteomic approaches.

Authors:  Pawel Ciborowski
Journal:  Biomark Med       Date:  2009-12       Impact factor: 2.851

Review 3.  The extended granin family: structure, function, and biomedical implications.

Authors:  Alessandro Bartolomucci; Roberta Possenti; Sushil K Mahata; Reiner Fischer-Colbrie; Y Peng Loh; Stephen R J Salton
Journal:  Endocr Rev       Date:  2011-08-23       Impact factor: 19.871

Review 4.  Proteomic Approaches to Decipher Mechanisms Underlying Pathogenesis in Multiple Sclerosis Patients.

Authors:  Vaibhav Singh; Ajai Tripathi; Ranjan Dutta
Journal:  Proteomics       Date:  2019-06-21       Impact factor: 3.984

5.  Application of mass spectrometry-based proteomics for biomarker discovery in neurological disorders.

Authors:  Abhilash Venugopal; Raghothama Chaerkady; Akhilesh Pandey
Journal:  Ann Indian Acad Neurol       Date:  2009-01       Impact factor: 1.383

6.  Proteomics comparison of cerebrospinal fluid of relapsing remitting and primary progressive multiple sclerosis.

Authors:  Marcel P Stoop; Vaibhav Singh; Lennard J Dekker; Mark K Titulaer; Christoph Stingl; Peter C Burgers; Peter A E Sillevis Smitt; Rogier Q Hintzen; Theo M Luider
Journal:  PLoS One       Date:  2010-08-27       Impact factor: 3.240

7.  Discovery of novel disease-specific and membrane-associated candidate markers in a mouse model of multiple sclerosis.

Authors:  Laura F Dagley; Nathan P Croft; Ruth Isserlin; Jonathan B Olsen; Vincent Fong; Andrew Emili; Anthony W Purcell
Journal:  Mol Cell Proteomics       Date:  2013-12-20       Impact factor: 5.911

8.  Fusion of metabolomics and proteomics data for biomarkers discovery: case study on the experimental autoimmune encephalomyelitis.

Authors:  Lionel Blanchet; Agnieszka Smolinska; Amos Attali; Marcel P Stoop; Kirsten A M Ampt; Hans van Aken; Ernst Suidgeest; Tinka Tuinstra; Sybren S Wijmenga; Theo Luider; Lutgarde M C Buydens
Journal:  BMC Bioinformatics       Date:  2011-06-22       Impact factor: 3.169

9.  Quantitative label-free proteomics for discovery of biomarkers in cerebrospinal fluid: assessment of technical and inter-individual variation.

Authors:  Richard J Perrin; Jacqueline E Payton; James P Malone; Petra Gilmore; Alan E Davis; Chengjie Xiong; Anne M Fagan; R Reid Townsend; David M Holtzman
Journal:  PLoS One       Date:  2013-05-20       Impact factor: 3.240

10.  Peptidome analysis of cerebrospinal fluid by LC-MALDI MS.

Authors:  Mikko Hölttä; Henrik Zetterberg; Ekaterina Mirgorodskaya; Niklas Mattsson; Kaj Blennow; Johan Gobom
Journal:  PLoS One       Date:  2012-08-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.